Biotech News
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates
ir.89bio.com2026-05-06 14:53 EST
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; each trial designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – ENTRUST Phase 3 topline data in severe